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There are indications from scattered case reports in the medical literature  of 
an  association  between  the  nephrotic  syndrome  and  a  variety  of  extrarenal 
malignancies in humans  (1-10).  Histologic examination  of renal  biopsies often 
revealed  a  membranous or membranoproliferative  glomerulonephritis  in  these 
patients  (1, 5, 8-10). Electron microscopic or fluorescent antibody studies indi- 
cated that the histologic alterations were associated with glomerular deposition 
of immune complexes.  Furthermore,  in one case,  immunoglobulin  eluted  from 
the kidney was reactive against autologous tumor cell membranes (8). 
In the course of examining tissues  for microscopic metastases  in C57BL/6J 
mice bearing  a  strain-specific melanoma  (B-16),  we routinely found histologic 
alterations of the renal glomeruli characterized by a mild proliferative glomeru- 
lonephritis  (Fig.  1). These mice had slightly elevated  urine protein levels,  but 
they were not significantly above normal limits. However, the histologic altera- 
tions of the kidneys were striking and were not due to metastatic infiltration or 
impairment of the renal blood supply by the tumor.  It was of interest  to deter- 
mine in what way this asymptomatic renal damage was related  to the presence 
and progress of the  tumor;  especially,  whether  it  reflected  the generation and 
deposition of soluble complexes of tumor antigen and antitumor antibody. Such 
complexes have been implicated  in the blockade of cell-mediated  tumor rejec- 
tion in other systems (11,  12). 
Materials and Methods 
The B-16 melanoma is a  transplantable,  strain-specific tumor of C57BL/6  mice, which 
was spontaneous in origin. Subcutaneous inoculation of l  X  105 cells produces a progressive, 
local, lethal growth in at least  70% of mice in our experience. The mice in this study were 
male C57BL/6 obtained from the Jackson Laboratories,  Bar Harbor,  Maine. 
Suspensions of tumor cells used in all assays and for in vivo immunization  or challenge 
* Supported  by National  Cancer  Institute  Grant  no. CA13658 and  Kentucky Tobacco 
Research Institute grant no. 073. 
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Fro.  1. (A) Kidney from normal 16-wk old C57BL/6J male mouse. (B) Kidney from 16-wk 
old  tumor-progressor  C57BL/SJ  male  mouse  showing prominent hypercellulaHty  and  in- 
creased mesangial matrix. X  400. Hematoxylin and eosin-stained 3/~ sections. 412  IMMUNE  COMPLEXES  IN  MALIGNANT MELANOMA 
were derived from nontrypsinized B-16 cells maintained in vitro in RPMI-1640 medium con- 
taining 15% heat-inactivated fetal calf serum, penicillin-streptomycin  (50 U/ml), and tylocine 
(anti-PPLO) at 37°C in 5% CO2 atmosphere. 
Detection  of Renal  Immunoglobulin  Deposits.--Kidneys  obtained from animals killed by 
cervical dislocation were washed in cold saline, frozen in a dry-ice acetone bath, and stored 
at --70  ° until sectioned. 6/z cryostat sections were fixed and stained as previously described 
(13).  Fhiorescein-conjugated, monospecific  antimouse  IgG,  IgM,  and  IgA  were  obtained 
from the Meloy Laboratory, Springfield,  Va. Fluorescence was examined with a Zeiss Photo- 
microscope (Carl Zeiss, Inc., New York)  equipped with an HBO 200 mercury vapor lamp, 
darkfield condenser, UG-1 exciter filter, and 47/65 barrier filter. 
Histology.--Histologic  examination of kidneys and  tumors was done on formalin-fixed, 
paraffin-embedded tissues. The sections were cut at 3 #  and stained with hematoxylin and 
eosin. 
In Vitro Assays for Cellular and Humoral  Reactivity.--Plasma  and peripheral blood leuko- 
cytes from  tumor-sensitized, tumor-progressor, and  tumor-rejector mice were  obtained at 
intervals by bleeding from the retroorbital sinus under light ether anesthesia using sterile 
heparinized capillary tubes. 0.4-0.5 ml of blood could be safely taken from individual animals 
at  10-day  intervals by  this method. The blood was centrifuged and  the plasma removed. 
Erythrocytes in the cell  pellet were lysed by incubation with Tris-ammonium chloride for 
10 min at 37°C. The leukocytes were washed four times with Hank's balanced salt solution 
to remove residual serum and lysing solution. The cell number and viability were determined 
by hemocytometer counting in an eosin Y solution (14). Wright's stained smears were pre- 
pared on random samples to determine the differential cell count. Leukocyte preparations 
showed greater than 95%  viability after lysing and washing, and were found to consist of 
97-100% lymphocytes. A yield of 1-2  X  106 viable lymphocytes could be obtained from 0.4- 
0.5  ml of blood by this technique. Each animal's plasma and leukocyte preparations were 
tested individually. 
In vitro cytotoxic activity of the peripheral blood lymphocytes (PBL) 1 was determined 
by admixture of 2  X  105 PBL with 1 X  105 [3H]TdR-labeled  (1.9 Ci/mmol, Schwartz-Mann 
Div., Becton, Dickinson & Co.,  Orangeburg, N. Y.)  B-16 cells (2:1  PBL: target cell ratio). 
The mixture was incubated at 37°C for 72 h in RPMI-1640 medium containing 5% fetal calf 
serum and the antibiotics described previously. During the incubation time the viable B-16 
cells adhere to the glass culture tube. The number of viable tumor cells remaining at the end 
of the incubation period was estimated by the retention of [3H]TdR in trichloroacetic acid- 
precipitable material in adherent tumor cells. Isotope counting was done in a liquid scintilla- 
tion system. Antibody cytotoxicity was determined in a similar fashion. The noncomplement 
inactivated plasma was diluted 1  : 10 in culture medium and the labeled tumor cells (1  X  105) 
were suspended in 0.25 ml of the diluted serum and incubated for 1 h at 37°C. The volume 
was then brought up to 1.5 ml by addition of culture medium and the incubation was con- 
tinued for 72 h. The viable target cells remaining were estimated by determining isotope re- 
tention as described above. The "blocking activity" of plasma was determined by first incu- 
bating the target cells with plasma as described for 1 h and then adding the PBL (2  X  10  ~) 
in a volume of 1.25 ml. Cytotoxicity was measured at 72 h as before. 
The relative titers of anti-B-16 membrane reactivity of the plasma were determined using 
a  mixed hemadsorption assay. B-16 cells were allowed  to adhere to the surface of the wells 
of Trans-Type  leukocyte-typing slides  (Hyland  Div.,  Travenol  Laboratories,  Inc.,  Costa 
Mesa, Calif.) and were subsequently incubated for 30 min at room temperature with dilutions 
of complement-inactivated mouse plasma. The monolayers were washed gently in phosphate- 
buffered saline (PBS) and two drops of a 0.5% suspension of doubly sensitized (mouse anti- 
1 Abbreviations  used  in this  paper:  GBM, glomerular basement membrane; MNL, mono- 
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SRBC/rabbit antimouse Ig) sheep red blood cells (SRBC) were added. Mter an additional 
30-min incubation at room temperature the monolayers were again gently washed by dipping 
in PBS and were read for adherence of SRBC. The titer was taken as the last dilution of 
plasma showing significant SRBC adherence to target cells. 
Elution of Renal Immunoglobulin.--Immunoglobulin was eluted from the kidneys of 9-wk 
old tumor-progressor mice by acid citrate  or chaotropic ions using the method described by 
Linder, et al. (15). The eluates are designated citrate eluate and KI eluate, respectively. 
Detection of Tumor Antigen in Plasma.--Individual  plasma pools were prepared from five 
groups of mice. The first pool was derived from mice sensitized with soluble B-16 antigen 
but not challenged with tumor.  2  These mice had demonstrable antitumor antibody. The second 
and third  pools were derived from tumor-progressor mice at day 10 and 20 post-challenge, 
respectively. The day  10 plasma had  no anti-B-16 antibody while the day  20 plasma did 
show significant antibody activity. The fourth pool was derived from day 20 plasma of ani- 
mals which subsequently spontaneously rejected a tumor challenge of 1 X  105 cells and had 
no demonstrable antibody activity.  The fifth pool was derived from control (nonsensitized, 
nonchallenged) mice. Each whole plasma pool was reacted in Ouchterlony double diffusion 
plates with rabbit antiserum against soluble B-16 antigen prepared as previously described.  2 
In addition,  a 3-ml sample of each plasma pool was applied to a Sephadex G-150 column 
(2.5 ×  45 cm) and eluted with PBS pH 7.4 at a flow rate of 10 ml/h. The excluded protein 
peak from each sample was concentrated by negative pressure dialysis and dialyzed against 
pH 3.0 saline to split antigen-antibody complexes. The samples were then dialyzed through 
an XM-50 Amicon membrane (Amicon Corp., Lexington, Mass.) with 10 vol of pH 3.0 saline. 
The dialysate, containing materials of less than 50#00 mol wt, was concentrated to one-half 
the original serum volume, dialyzed against pH 7.4 saline, and tested for the presence of B-16 
specific antigen in double diffusion against rabbit anti-B-16SA antiserum. 
RESULTS 
The  intensity of  immunoglobulin deposition  in  representative  tumor-pro- 
gressor and age-matched control mice is shown in Table I. IgG, IgM, and IgA 
deposits in the kidneys of tumor-progressor mice were always greater than in 
age-matched  controls,  although  age-related,  spontaneous complex  deposition 
involving all three immunoglobulin  classes did occur. IgG deposits showed the 
most consistent and most profound elevation in the tumor-progressor mice and 
always involved the  glomerular basement membrane (GBM)  as  well  as  the 
mesangium; whereas in control mice the deposits, when present, were confined 
to the mesangium. The immunofluorescence staining pattern of glomeruli from 
tumor-progressor mice is shown in Fig. 2. The deposits were clearly granular in 
nature and appeared in 100% of the glomeruli in affected mice. Since an under- 
lying, age-associated immune-complex disease has been described in this mouse 
strain (15, 16)  and was confirmed by these data, further studies were confined 
to mice younger than 16 wk of age. 
It was necessary to determine whether the increased intensity and GBM in- 
volvement of immune-complex  deposition in tumor-progressor mice represented 
acceleration of an ongoing disease due to  the physiologic stress of a  growing 
Poskitt,  P. K. F., T. R. Poskitt, and J. H. Wallace. 1974. Spontaneous release of mem- 
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TABLE I 
Age-  and  Tumor-Rdated  Renal  Immunoglobulin  Deposition 
Tumor status  Age 
Intensity  and distribution*  of renal immunoglobulin 
IgG  IgM  lgA 
Control (not challenged) 
wk 
II  0-tr  m  0  0 
II  0  0  0 
II  0  0  0 
11  O-tr m  0  0 
22  1+ m  tr m  tr-l+ m 
22  1+ ra  1+ m  1+ m 
22  1+ m  1+ m  tr m 
22  1+ m  1+ m  tr m 
Bearing  a  progressive  subcu- 
taneous tumor 
11  3+ g  1-2+ m, g  tr m 
11  2-3+ m, g  2-3+ m, g  tr m 
11  2+ m, g  2+ m, g  tr-l+ m 
11  2+ m, g  1+ m, g  tr m 
11  2+ m, g  2-3+ m, g  tr m 
22  3+ m, g  2+ m, g  2-3+ m, g 
22  2-3+ m, g  1+ m  1+ m, g 
22  2+ m, g  tr-l+ m  2+ m, g 
22  2+ m, g  tr-l+ m  tr-l+ m 
The values are shown for individual animals. Tumor-bearing animal's kidneys were ex- 
amined 20-25 days after s.c. challenge with 1 X l0  s B-16 cells. 
* ra indicates mesangial localization of deposits, g indicates GBM localization of deposits. 
tumor, or whether it represented the generation of new immune complexes in- 
volving soluble tumor antigen. Table II shows  the  relative intensity of  IgG 
deposition and antitumor serum antibody titers in ll-wk old animals which had 
progressive tumors, in animals which were sensitized with soluble tumor anti- 
gen  2 but not challenged, in immunosuppressed tumor-progressor animals, and 
in animals which spontaneously rejected a tumor challenge. It appears that the 
complexes are, in fact, related to the presence of the tumor as an antigen rather 
than  as  a  physiologic stress.  Animals sensitized and challenged with  soluble 
tumor antigen all showed greater than 2  +  IgG immune complex deposition as 
did animals bearing progressive tumor. However, animals which spontaneously 
rejected the  tumor and tumor-progressor animals which had been pretreated 
with a  dose of irradiation which preferentially suppresses primary immune re- 
sponses all showed renal IgG deposits of 1+ or less. These results suggested that 
the renal deposits might represent soluble circulating complexes of tumor anti- 
gen and antitumor antibody. 
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FIG. 2.  (a)  Tumor-progressor glomerulus stained with anti-IgG FITC showing granular 
mesangial and GBM deposits.  (b) Tumor-progressor glomerulus stained with anti-IgM FITC. 
Deposits  are primarily mesangial.  (c)  Tumor-progressor glomerulus stained with  anti-IgA 
FITC. Deposits are primarily mesangial. (d) Age-matched nontumor-bearing  control stained 
with anti-IgM FITC. X  200. 416  IMMUNE COMPLEXES IN  MALIGNANT MELANOMA 
TABLE II 
Renal  IgG Deposition  in  11-Wk Old  Tumor  Challenged and  Soluble  Antigen-Sensitized  Mice 
Fraction with renal IgG* deposits  scored as:  Group average 
Group  ab. titer~  ._<1+  >i + _<2+  >2+ 
Tumor progressors  0/5  0/5  5/5  1  : 200 
Soluble antigen-sensitized  §  0/5  0/5  5/5  1 : 3200 
Tumor  progressors  (immunosup-  5/5  0/5  0/5  <1:10 
pressedlD 
Tumor rejectors  5/5  0/5  0/5  < 1  : 10 
Control  5/5  0/5  0/5  < 1  : t0 
* Renal IgG deposits determined by indirect immunofluorescence. 
:~ Serum antibody (ab.) titer determined by mixed hemadsorption assay. 
§ 50 lag of soluble B-16 antigen given s.c. in adjuvant day 0; 150/zg given i.p. day 22. 
I[ 450 R whole-body irradiation 2 days before challenge. Serum and kidneys were examined 
24 days after  the initial sensitization or challenge. The classification of progressors and re- 
jectors is based on the presence or absence of a palpable tumor at the time of examination. 
In our experience, animals which have palpable tumors at this stage always die of the tumor. 
Animals which do not have palpable tumors by day 24 always survive the tumor and are 
resistant to subsequent challenges. 
FxG. 3.  Indirect irnmunofluorescence  for IgG antibody activity against  B-16 cell mem- 
branes. (a) Pooled (KI and citrate) renal eluate from tumor-progressor mice. (b) Pooled un. 
diluted serum from tumor-progressor mice. (See Table III for titers and specific activity). 
progressor  mice and examined by indirect immunofluorescence for  reactivity 
with  the  B-16  tumor cell membranes. Tumor-bearing mice in this age  group 
showed only IgG in renal deposits. The fluorescent staining pattern is shown in 
Fig. 3.  Table III shows  the  relative activity and specificity for B-16 cells of 
renal eluates and serum derived at the same time from the same animals. The 
specific activity for B-16 cell membranes of IgG in the pooled KI and citrate 
eluates was 32 times greater than in the serum (relative to the IgG concentra- 
tion). Neither the serum nor the pooled eluate reacted with C57 liver cells or P.  K.  F.  POSKITT,  T.  R.  POSKITT,  AND  J'.  H.  WALLACE  417 
erythrocytes in an indirect immunofluorescence assay and the activity against 
B-16  cells  could not be  removed by absorption with C57 tissue powder. IgM 
and IgA could not be detected in the eluates and no IgM or IgA antibody was 
detected in the indirect fluorescence assay with B-16  cells,  C57  liver cells, or 
erythrocytes. 
The relationship of the renal IgG deposits to tumor size, intensity of mono- 
nuclear leukocyte (MNL) infiltration, and the presence of lung metastases is 
shown in Table IV. In general, mice which showed only small amounts (< l-l-) 
TABLE  III 
Antibody Activity of Plasma and Renal Eluates from Tumor-Bearing Mice 
Sample  Absorption*  IgG titer vs. B-16~t Specific  activity§ 
Plasma  --  8  1 
Citrate eluate  --  2  32 
KI eluate  --  4  64 
Plasma  C57 tissue powder  8  1 
Pooled KI and citrate eluate  C57 tissue powder  2  32 
Plasma  B-16 cell powder  0  0 
Pooled KI and citrate eluate  B-16 cell powder  0  0 
* Absorption carried out with equal volumes of plasma or eluate and lyophilized tissue 
powder. 
:~ IgG titer vs B-16 determined by indirect immunofluorescence. Similar tests using anti- 
IgM or IgA were negative. Indirect fluorescence  was negative for all  three immunoglobulin 
classes against C57 liver cells and erythrocytes. 
§ IgG anti-B-16 specific activity relative to unabsorbed plasma. 
eluate titer  plasma IgG concentration 
Spec act -  X 
plasma titer  eluate IgG concentration 
TABLE  IV 
Relationship of Renal IgG Deposits to In Vivo Parameters of Tumor Growth 
Renal IgG deposits  scored  as: 
<1+  >1+ _<2+  >2+ 
Fraction of tumor progressors in each cata-  13/33 
gory 
Fraction of animals with MNL infiltrate of 
tumor scored as: 
None  0/13 
Mild  1/13 
Moderate  7/13 
Pronounced  5/13 
Fraction of animals with lung metastases  0/13 
Tumor volume (mmS) Range  150-1,800 

















Eight age-matched control mice showed renal IgG of 0-tr. 418  IMMUNE  COMPLEXES  IN  MALIGNANT MELANOMA 
of renal deposits of IgG had relatively small tumors at the injection site and the 
tumors had moderate to pronounced MNL infiltration (Fig. 4 a). A correlation 
between a  favorable prognosis and intense lymphocytic infiltration has been 
reported in human malignant melanoma (17). None of these animals had metas- 
tases to the lungs. Mice which showed moderate (> 1+  <2+)  renal IgG de- 
posits had somewhat larger tumors with relatively less  MNL infiltration. One 
animal  had lung  metastases.  Mice which had large (> 2+)  amounts of renal 
IgG had the largest tumors with little or no MNL infiltration (Fig. 4 b) and 5 
out of 10 had microscopic lung  metastases. All parameters were examined at 
24-26 days after tumor inoculation. 
The extreme variability (none to pronounced) of the intensity of MNL in- 
filtration of the tumors suggests that there is a difference in the cell-mediated 
tumor rejection response in these animals which is related to immune complex 
deposition. However, in vitro testing of PBL from similar animals  (Table V) 
revealed  that  all  tumor-progressor  animals  had  some  degree  of  PBL  cyto- 
toxicity against B-16 cells at day 20 after tumor inoculation. PBL cytotoxicity 
was not found in any animals at day 10. The intensity of day 20 PBL reactivity 
did  not  correlate with  the  tumor size  at  day 20 or with  the  time of death. 
Furthermore, animals which spontaneously rejected the tumor had essentially 
identical PBL reactivity as did animals which succumbed to the tumor. 
Humoral antibody activity in the tumor-progressors and tumor-rejectors is 
shown in Table VI. Day 20 post-tumor inoculation antibody titers of individual 
tumor-progressor plasmas  did not  differ significantly.  Both  cytotoxicity and 
blocking activity could be demonstrated in the same plasma at the same dilution 
in some of the progressor animals. In some cases, where blocking activity was 
not found, the plasma and PBL combination resulted in enhanced (greater than 
additive)  cytotoxicity implying perhaps an antibody-dependent cellular cyto- 
toxicity. Animals  which  had  cytotoxic antibody or  whose  i)lasma  enhanced 
cellular cytotoxicity did not survive significantly longer  than  those which did 
not; nor did the presence of plasma blocking activity correlate with shortened 
survival time. Tumor-rejectors, as a group, had no detectable antitumor anti- 
body at day 20 by mixed hemadsorption, cytotoxic, or blocking assays. Mice 
sensitized to the B-16 tumor with either killed (irradiated or frozen) tumor cells 
or with soluble tumor antigen  2 developed both cellular and humoral responses 
comparable to those in tumor-progressor animals. When the sensitized animals 
were subsequently challenged with a tumor inoculum (5 X  104 cells)  which did 
not  take  in  control  animals,  they  all  developed  progressive,  lethal  tumors 
(Table VII). These animals showed the most pronounced (all > 2+) renal IgG 
complex deposition and the least  amount of MNL infiltration of the  tumors 
of any animals tested. 
Of the five unfractionated plasma pools tested,  tumor-specific antigen was 
found only in one. This was the pool consisting of day 10 serum from tumor- 
progressor mice which had not shown antibody activity. However, after frac- Fro. 4. Hematoxylin and eosin-stained sections of subcutaneous B-16 melanoma. (a) from 
a representative animal with  >2+  renal IgG showing healthy tumor ceils around blood vessel 
with no MNL infiltrate. X  200.  (b) From a representative animal with <1+  renal IgG show- 
ing MNL infiltrate surrounding blood vessel and dead or dying tumor cells in the vicinity of 
the infiltrate. X  200. 
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TABLE  V 
Rdationship of In Vitro PBL Cytotoxi~ity to Tumor Progress 
Tumor status  PBL % cytotoxicity*  Day of death 
Progressor  76  33 
54  25 
54  30 
53  38 
38  50 
37  42 
31  37 
Rejector  49  -- 
47 
29 




* In vitro PBL cytotoxicity vs. [3H]TdR-labeled B-16 cells. All animals were  tested  indi- 
vidually on day 20 post-challenge. Control are animals which were not tumor challenged. 
TABLE  VI 
Rdatlonship of Humoral Antibody to Tumor Progress 





320  40  +  +  +  +  42 
320  22  0  33 
160  22  +++  38 
160  25  ++  25 
160  28  ++++  30 
160  0  0  50 
80  0  0  37 
<10  0  0 
<10  0  0 
<10  0  0 
<10  0  0 
<10  0  0 
<10  0  0 
<10  0  0 
m 
E 
All animals were tested individually on day 20 post-challenge. Controls are animals which 
were not tumor challenged. 
* Reciprocal of last positive dilution in mixed hemadsorption assay vs. B-16 cells. 
:~ Percent [3H]TdR-labeled B-16 cells killed by a  1:10 dilution. 
§ Percent inhibition of autologous PBL cytotoxicity by a  1 : 10 dilution. 0, none; +,  -< 25%; 
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TABLE  VII 
Effect  of Presensitization  on Take  and  Progress of Subsequent  Tumor Challenge 
No.  No. takes  Time of take*  Time of death*  No.  Treatment group  animals  survivors 
Saline control  8  0  --  --  8 
Multiple injections of killed  10  10  15 (10-17)  29 (25-34)  0 
tumor 
Multiple injections of soluble  6  6  13 (10-16)  28 (26-30)  0 
tumor antigen 
Animals challenged with 5  X  104 live B-16 (s.c.) 2 wk after the last immunizing injection. 
* Indicates days after tumor challenge. The average and range are shown for the day of 
take (palpable tumor) and death. 
tionation and low pH immune complex dissociation, free antigen was detected 
in both the day 10 and day 20 tumor-progressor plasma. Tumor antigen could 
also be detected in the citrate (pH 3.0)  eluates from day 20 tumor-progressor 
kidneys. 
DISCUSSION 
We have reported previously  ~ that in vilro cultured B-16 cells spontaneously 
release  a  soluble,  tumor-specific membrane  antigen  (20,000-27,000  mol  wt), 
and that antigen release occurs both through active metabolism and autolysis. 
It appears that a similar antigen (less than 50,000 mol wt) is shed in vivo, as 
evidenced by the detection of free or antibody-complexed antigen in the serum 
and in renal deposits of tumor-progressor animals. Furthermore, the intensity 
of renal immune complex deposition showed a more consistent correlation with 
in  vivo parameters  of  tumor growth  (size  and  metastatic spread)  and  host 
rejection response  (MNL infiltration) than did in vitro assays for peripheral 
blood lymphocyte cytotoxicity, antibody titer, cytotoxic antibody or blocking 
antibody. Lymphocyte cytotoxicity assays at  a  low lymphocyte: target  cell 
ratio (2:1) failed to discriminate between tumor-progressors and rejectors, and 
the level of cytotoxicity did not correlate with survival time in progressors. 
Tumor-reactive antibody (mixed hemadsorption assay) was consistently found 
in progressor animals; however, functional assays for cytotoxicity and blocking 
activity were poor indicators of tumor progress with regard to the most signifi- 
cant criterion, namely, survival. 
The existence of tumor antigen in the serum of tumor-bearing individuals has 
been described previously (11,  12, 18,  19)  and such serum has been shown to 
block  in  vitro  lymphocyte cytotoxicity presumably by interaction with  the 
lymphocyte antigen receptors (11, 12, 18). In other systems, however: humoral 
blocking activity appears  to  be  a  property of noncytotoxic antibody which 
masks the tumor cell antigens (20). The definition of "blocking" activity is quite 
dependent on the way the serum is assayed. Thus, if serum is preincubated with 
target cells  and removed before addition of the lymphocytes, only "masking 422  IMMUNE  COMPLEXES  IN  MALIGNANT  MELANOMA 
antibody" can be detected. If the serum is preincubated with the lymphocytes, 
on  the other hand,  only antigen blockade of T-lymphocyte receptors can be 
detected. 
Fig. 5 shows the interactions which might occur between soluble circulating 
tumor antigen and immune effectors. In  this scheme, the biological effects of 
antibody and T lymphocytes are proposed to be controlled by fluctuating levels 
of soluble antigen. In conditions of antigen excess, free or antibody-complexed 
antigen may bind to T-lymphocyte antigen receptors and thus activate the cells. 
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Fzo. 5. Interactions of soluble tumor antigen with immune effectors. 
These lymphocytes would be stimulated at a distance from the tumor mass and 
would  therefore expend  their short-range effectors (MIF,  lymphotoxin, etc.) 
without causing damage to the tumor. Thus, one might expect that in individ- 
uals with massive tumor burdens delayed hypersensitivity responses to addi- 
tional tumor antigen might be minimal or absent. In a study of eight patients 
with malignant melanoma, Fass et al.  (21)  found that only those with small, 
localized tumors (3/8) showed delayed hypersensitivity reactions to autologous 
tumor cells. The five patients with disseminated disease were unreactive. These 
~esults were not a reflection of general anergy as all eight patients showed normal 
delayed hypersensitivity reactions to other antigens to which they were previ- 
ously sensitive. 
Furthermore, antigen-antibody complexes bound by T  lymphocytes might 
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lesser reactivity in vitro of washed lymphocytes from melanoma patients with 
disseminated tumors (22). Thus, it is possible to deplete the effective T-lympho- 
cyte population to the point where even a  strongly sensitized individual will 
appear unreactive. 
In the B-16 system, the C57BL/6 host does not have a complete hemolytic 
complement system and so depletion of reactive lymphocytes by lysis may not 
occur. In fact, when peripheral blood lymphocytes were removed from animals 
with varying degrees of tumor mass and washed thoroughly, they behaved very 
similarly. On the other hand, the in vivo effectiveness of the lymphocytes as 
measured by MNL infiltration of the tumor was markedly different in animals 
with large and small tumors. Thus, the potential activity of the lymphocytes 
was the same regardless of tumor mass, but their actual effectiveness was di- 
minished in animals with larger tumors. This suggests the possibility that di- 
minished lymphocyte reactivity in vivo could be an effect rather than a cause 
of  rapid  tumor  growth  and  consequent  release  of  large  amounts  of  tumor 
antigen. 
Referring again to Fig. 5,  in conditions of slight antibody excess,  the phe- 
nomenon of masking tumor  cell  antigens by antibody present in insufficient 
quantities  to  be  cytotoxic  (by  complement  fixation or  antibody-dependent 
cellular cytotoxicity) may occur. Whereas, in conditions of extreme antibody 
excess,  brought about by removal of part of the tumor mass and decrease in 
available circulating antigen, the same antibody which previously "masked" 
might become cytotoxic. For example, Lewis et al. (23) have reported the  ap- 
pearance of cytotoxic antibody in two previously negative patients following 
partial excision of their malignant melanoma. Furthermore, inhibition of serum- 
blocking activity by the serum of patients in remission (24)  may reflect the 
attainment of a balance of antigen and antibody in the mixture of the two types 
of sera resulting in effective neutralization of both antigen and antibody. 
The postulated interaction presented in Fig. 5 is not meant to represent al- 
ternative static conditions, but rather a cycle which is controlled chiefly by the 
availability of circulating antigen. Since we have shown  2 that soluble antigen 
can be released by autolysis following tumor cell death as well as by living cells, 
it is possible that vigorous immunologic attack of the tumor may be ultimately 
self-defeating by accelerating the release of soluble antigen. 
Monitoring  of  renal  immune  complex  deposition  in  one  reported  case  of 
Hodgkin's disease (5) proved to be useful for following and, in fact, predicting 
the course of the disease. At present, renal biopsies are usually performed only 
on cancer patients with obvious renal complications; however, the study re- 
ported here suggests that significant immune complex deposition can occur in 
tumor-bearing individuals without clinical evidence of renal disease.  Examina- 
tion of this phenomenon in a selected series of cancer patients could establish 
its general occurrence and possible prognostic value. 424  IMMUNE  COMPLEXES  IN  MALIGNANT  MELANOMA 
SUMMARY 
Histologic and immunofluorescence studies of the kidneys of mice bearing a 
progressive melanoma show a proliferative glomerulonephritis associated with 
immune complex deposition in the mesangium and along the glomerular base- 
ment membrane  This immune complex disease is distinct from the age-associ- 
ated disease of the C57BL/6J host strain and the complexes can be shown to 
consist  of soluble  tumor  antigen  and  antitumor  antibody.  Furthermore,  the 
intensity  of IgG complex deposition  correlates  directly  with  tumor progress 
(size and metastases) and inversely with mononuclear leukocyte infiltration of 
the tumor. In vitro assays for lymphocyte cytotoxicity and humoral antibody 
were found to be less reliable indicators of tumor progress. The possible role of 
circulating soluble tumor antigen in modifying the immune response to tumors 
is discussed. 
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